Veeva vs. IQVIA: Which Life Sciences Tech Stock Holds More Promise? - TradingView

Veeva just spent another earnings call talking about their "next-generation CRM platform" — and if you work in life sciences, you already know what that means for you.

It means more roadmap promises. More waiting. More "that feature is coming in Q3" while your reps are still copy-pasting account notes into spreadsheets because the system doesn't capture what they actually need to capture.

Veeva and IQVIA are publicly traded companies. Their CRM decisions are made for shareholders first, industry verticals second, and your specific workflow somewhere further down the list. That's not cynicism — that's just how enterprise software works.

If you've already been through one CRM overhaul that didn't stick, you know the pattern: the demo looks clean, the contract gets signed, and six months later you're managing the same chaos on a different interface.

The real question isn't which big vendor holds more promise for investors. It's whether any vendor-driven roadmap will ever move fast enough to match how your business actually changes quarter to quarter.

It won't — and the sooner you stop waiting on their release schedule, the sooner your ops actually work.

#CRM #LifeSciences #SalesOps #CRMStrategy #MidMarket

Original Source

... CRM, its next-generation customer relationship management platform. During the fourth quarter of fiscal 2026 earnings call, management highlighted ...